Trial Profile
A study evaluating predictive role of insulin receptor expression for resistance to axitinib in patients with advanced renal cell carcinoma.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Mar 2017
Price :
$35
*
At a glance
- Drugs Axitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 21 Mar 2017 New trial record
- 18 Feb 2017 Results presented at the 2017 Genitourinary Cancers Symposium